MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
MyoKardia, Inc's (MYOK) MYK-461 HCM Study Should Show Clinical Benefit - Wedbush
May 13, 2016 8:03 AM EDTWedbush analyst, David M. Nierengarten, believes biomarker-based efficacy readouts from a Ph 1 study of MyoKardia (NASDAQ: MYOK) MYK-461 in HCM patients are expected this quarter, which should provide further evidence of the drugs activity. No change to Outperform rating or $22 price target
Top-line... More
